Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares of the company’s stock, valued at approximately $5,273,100.81. The trade was a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00.
• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $16.63 on Friday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -10.87 and a beta of 1.53. The company’s 50 day moving average is $16.71 and its 200 day moving average is $15.83. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Centessa Pharmaceuticals in the third quarter worth $2,834,000. Wellington Management Group LLP purchased a new position in Centessa Pharmaceuticals in the third quarter worth $1,609,000. State Street Corp purchased a new position in Centessa Pharmaceuticals in the third quarter worth $777,000. Ally Bridge Group NY LLC purchased a new position in Centessa Pharmaceuticals in the third quarter worth $4,951,000. Finally, GSA Capital Partners LLP grew its holdings in Centessa Pharmaceuticals by 66.1% in the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after purchasing an additional 37,275 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.